Truvestments Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Truvestments Capital’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13K	Buy	766 +329	+75%	+$5.26K	﹤0.01%	752
2026 Q1	$6.48K	Hold	437	–	–	﹤0.01%	840
2025 Q4	$6.97K	Hold	437	–	–	﹤0.01%	747
2025 Q3	$4.83K	Hold	437	–	–	﹤0.01%	827
2025 Q2	$3.7K	Hold	437	–	–	﹤0.01%	773
2025 Q1	$3.51K	Hold	437	–	–	﹤0.01%	791
2024 Q4	$3.92K	Hold	437	–	–	﹤0.01%	732
2024 Q3	$3.2K	Buy	+437	New	+$2.71K	﹤0.01%	741
2024 Q2	–	Sell	-687	Closed	-$3.44K	–	259
2024 Q1	$3.44K	Hold	687	–	–	﹤0.01%	579
2023 Q4	$6.18K	Hold	687	–	–	﹤0.01%	570
2023 Q3	$5.34K	Hold	687	–	–	﹤0.01%	508
2023 Q2	$6.65K	Hold	687	–	–	﹤0.01%	495
2023 Q1	$7.53K	Buy	687 +487	+244%	+$4.29K	﹤0.01%	466
2022 Q4	$864	Hold	200	–	–	﹤0.01%	839
2022 Q3	$2K	Hold	200	–	–	﹤0.01%	541
2022 Q2	$2K	Buy	+200	New	+$2.24K	﹤0.01%	549

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Truvestments Capital's AUPH Position: Q2 2026 in Review

Truvestments Capital increased its Aurinia Pharmaceuticals (AUPH) stake by 75% in Q2 2026, buying an estimated $5.26K and bringing the position to 766 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #752.

Truvestments Capital first reported a position in AUPH in Q2 2022 and has held it in 16 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Truvestments Capital held 766 shares of Aurinia Pharmaceuticals worth $13K as of Q2 2026.
Truvestments Capital bought 329 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $5.26K.
Aurinia Pharmaceuticals made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #752 holding.
Truvestments Capital first reported a position in Aurinia Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.